Judith Gulikers

UCSF Cardiovascular Research Institute

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Toine Egberts

Utrecht University

NETHERLANDS

View details

Johanna Driessen

University of Maastricht

NETHERLANDS

View details

Robin van geel

University of Maastricht

NETHERLANDS

View details

Lourens Bloem

Utrecht University

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Judith Gulikers

Research Interests

Explore related searches

Contact this professor

Articles (10)

Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer

Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results

Comparison of characteristics of patients with lung cancer in UK primary care databases

Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.

Development and validation of an HPLC–MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2‐EDTA plasma

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Collaborators (4)

Toine Egberts

Johanna Driessen

Robin van geel

Lourens Bloem

Make your next move.